Treatment of human brucellosis with rifampin plus minocycline

Research output: Contribution to journalArticlepeer-review

27 Citations (Scopus)


In order to evaluate the efficacy and tolerability of a high intravenous dose of rifampin plus oral minocycline (administered daily for 3 weeks) for the treatment of acute brucellosis, we retrospectively reviewed the outcome of 239 consecutive patients (135 adults and 104 children) diagnosed and treated over a 17-year period in Italy. The combination used resulted in 100% response and a relapse rate lower than 2%. Fifty-two (30 adults and 22 children) (29.8%) complained of mild adverse effects including an increase in aspartate aminotransferase (>250 IU) observed in 12 cases and considered related to rifampin and in 11 cases a reversible hyperpigmentation of the tongue attributed to minocycline. A randomized prospective comparative study should be performed to confirm our encouraging results
Original languageEnglish
Pages (from-to)248-252
Number of pages5
JournalJournal of Chemotherapy
Publication statusPublished - 2003

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases


Dive into the research topics of 'Treatment of human brucellosis with rifampin plus minocycline'. Together they form a unique fingerprint.

Cite this